Cellectis S.A. business relationships
Companies named in Cellectis S.A.’s 20-F filed 2026-03-20, and public companies whose annual reports name Cellectis S.A.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 72 / 100 Top 2% in its category
- Agent readiness
- 30 / 100
- AI adoption
- 0 / 100
Named in Cellectis S.A.’s annual report 11
“For the year ended December 31, 2025, one customer represents more than 10% of the total revenue: AstraZeneca with 99 %.” SEC filing
“...and successfully commercialize our most advanced product candidates lasme-cel and eti-cel, our ability to develop and manufacture product candidates for AstraZeneca, and the ability of our licensees or partners to advance the product candidates that they are developing pursuant to licenses from us.” SEC filing
“For the twelve-month period ended December 31, 2025, we mainly derived our Therapeutics revenues from the JRCA with AstraZeneca, and from other license agreements for the use of our gene editing technology.” SEC filing
“Pursuant to the Collaboration and License Agreement, Pfizer made an upfront, non-refundable $80.0 million payment to us.” SEC filing
“For the year ended December 31, 2025, our revenues denominated in U.S. dollars are mainly related to AstraZeneca collaboration agreement.” SEC filing
“...e 2014, we entered into a Research Collaboration and License Agreement (the "Collaboration and License Agreement") with Pfizer, Inc. ("Pfizer") pursuant to which we agreed to collaborate to conduct discovery and pre-clinical development activities to generate CAR T-cells directed at Pfizer- and Cell...” SEC filing
“Our net cash flows provided by financing activities of $89.2 million were mainly driven by the closing of the SIA with AstraZeneca which resulted in net cash proceeds of $139.8 million cash, of which $57.0 million were recorded as cash-flows from operating activities and $82.8 million as financing a...” SEC filing
“Research Collaboration and Exclusive License Agreement with Iovance Biotherapeutics” SEC filing
“We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca under which our partners have or have the right to obtain exclusive development and commercialization rights with respect to certain product candidates.” SEC filing
“our receipt of milestone or royalty payments pursuant to our licensing agreements with Allogene Therapeutics, Inc. ("Allogene"), Les Laboratoires Servier and Institut de Recherches Internationales Servier (together "Servier") and AstraZeneca Ireland Limited ("AZ Ireland");” SEC filing
“On December 29, 2022, we entered into a Collaboration Agreement with Primera Therapeutics, Inc. ("Primera") (the "Primera Collaboration Agreement").” SEC filing
Companies whose annual reports name Cellectis S.A. 5
“...h collaboration and exclusive worldwide license agreement whereby the Company will license gene-editing technology from Cellectis S.A. ("Cellectis"), a clinical-stage biopharmaceutical company, to develop TIL cell therapies that have been genetically edited, including a PD-1 inactivated product that...” SEC filing
“As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis).” SEC filing
“License Agreement dated July 25, 2017 between Cellectis S.A. and Cibus, Inc. (f/k/a Calyxt, Inc.) (incorporated by reference to Exhibit 10.5 of the Company's Annual Report on Form 10-K filed with the SEC on March 14, 2018)” SEC filing
“In addition, our cross-license agreement (the "Cellectis License") with Cellectis S.A. ("Cellectis") imposes various obligations on us in order to maintain the license.” SEC filing
“See "-License and Collaboration Agreements-Cellectis S.A." above for additional information regarding the Cellectis License.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.